Neuroscience News and Research

RSS

New study may lead to in-car warning system that may provide enough time for drivers to react

It is well-documented that when negotiating winding roads, drivers tend to look at a specific, well-defined point on the lane marking - referred to as the tangent point. New research finds that the further drivers can look ahead, generally in left-hand curves, wide curves and when leaving a curve, the less they have to look at the tangent point.

7 Jul 2010

Rejection by romantic partner associated with brain's motivation, reward and addiction craving centers

Researchers have linked rejection by a romantic partner to brain activity associated with motivation, reward and addiction cravings, according to a study published in the July issue of the Journal of Neurophysiology. Lucy Brown, Ph.D., clinical professor in the Saul R. Korey Department of Neurology and of neuroscience at Albert Einstein College of Medicine of Yeshiva University, is the corresponding author of the study.

7 Jul 2010

Scientists demonstrate how neural stem cells, precursor cells control growth of glioblastomas

In their latest research, scientists of the Max Delbr-ck Center for Molecular Medicine Berlin-Buch, Germany, have demonstrated how the brain's own stem cells and precursor cells control the growth of glioblastomas. Of all brain tumors, glioblastomas are among the most common and most aggressive.

7 Jul 2010

ERA-Net NEURON names winners of 2009 Excellent Paper in Neuroscience award for young scientists

ERA-Net NEURON, an initiative of the European Commission aimed at advancing transnational European research in the field of disease-related neuroscience, announced today the winners of the Excellent Paper in Neuroscience award for young scientists for the year 2009.

6 Jul 2010

Depression increases risk of developing dementia later in life

A new study shows that having depression may nearly double your risk of developing dementia later in life. The research will be published in the July 6, 2010, issue of Neurology-, the medical journal of the American Academy of Neurology.

6 Jul 2010

The heart and the psyche – Link between heart disease and anxiety-depressive disorders

According to a new report published in the acclaimed journal Archives of General Psychiatry, concomitant anxiety and other psychiatric illnesses in heart patients raise their risk of getting heart attacks, strokes, heart failure and early death.

5 Jul 2010

Karolinska Institutet researchers contribute at ESOF 2010

Researchers and staff from Karolinska Institutet are contributing to Europe's largest cross-disciplinary gathering place with news of everything from neuroscience to bioentrepreneurship. Carl Johan Sundberg, university lecturer and associate professor at Karolinska Institutet, is the founder and initiator of ESOF.

3 Jul 2010

Wellcome-Wolfson Capital Awards initiative invests over 30M in large-scale university infrastructure projects

Over -30 million is being invested into large-scale university infrastructure projects courtesy of the Wellcome-Wolfson Capital Awards initiative.

3 Jul 2010

Study: ONGLYZA and metformin improve HbA1c levels for adult patients with type 2 diabetes at 76-weeks

Bristol-Myers Squibb Company and AstraZeneca today announced results up to 76-weeks from a Phase 3 study of ONGLYZA(TM) (saxagliptin) as initial combination therapy with metformin, which produced long-term glycemic improvement (as measured by glycosylated hemoglobin level (HbA1c)) in treatment-naive adults with type 2 diabetes mellitus inadequately controlled on diet and exercise compared to treatment with an investigational 10 mg dose of saxagliptin or metformin alone.

2 Jul 2010

Research may provide key to understanding interplay between exercise, aging and neurogenesis

Stem cells in the brain remain dormant until called upon to divide and make more neurons. However, little has been known about the molecular guards that keep them quiet.

2 Jul 2010

AstraZeneca announces new support program for patients on ARIMIDEX

AstraZeneca today announced a new patient support program for postmenopausal women with hormone receptor-positive early breast cancer who are prescribed ARIMIDEX. The program is designed to provide eligible patients with instant discounts, potentially saving the patient up to $300.

1 Jul 2010

Euthymics and DOV sign merger agreement

Euthymics Bioscience, Inc., a privately held Delaware corporation, and DOV Pharmaceutical, Inc., a Delaware corporation currently traded on the Pink Sheets, today jointly announced that they have signed a merger agreement in connection with the pending merger and acquisition of DOV by Euthymics.

1 Jul 2010

University College London neurology professor becomes first recipient of Lord Brain Memorial Medal

Andrew Lees, Professor of Neurology at University College London, is to be the first ever recipient of the Lord Brain Memorial Medal - awarded for the scientific contributions he has made to the field of movement disorders within the UK. He will receive the medal following his delivery of the inaugural Lord Brain Memorial Lecture; "Brainwashed by the Black Stuff," at Barts and The London Medical School on June 24, 2010.

1 Jul 2010

Brain is intrinsically unreliable, says new research

Next time your brain plays tricks on you, you have an excuse: according to new research by UCL scientists published today in the journal Nature, the brain is intrinsically unreliable.

1 Jul 2010

New research identifies memory and brain scan as best tests for predicting Alzheimer's disease

New research has identified the memory and brain scan tests that appear to predict best whether a person with cognitive problems might develop Alzheimer's disease. The research is published in the June 30, 2010, online issue of Neurology, the medical journal of the American Academy of Neurology.

1 Jul 2010

Eisai to commercialize lorcaserin for obesity and weight management in U.S.

Arena Pharmaceuticals, Inc. today announced that Eisai Inc. will market lorcaserin for obesity and weight management in the United States following U.S. Food and Drug Administration (FDA) approval under the terms of a marketing and supply agreement between Arena Pharmaceuticals GmbH, a wholly owned subsidiary of Arena Pharmaceuticals, Inc., and Eisai. Lorcaserin, which Arena discovered and has developed for weight management, is intended for obese patients as well as overweight patients who have at least one weight-related co-morbid condition.

1 Jul 2010

Eisai signs agreement with Arena Pharmaceuticals GmbH to commercialize lorcaserin

Eisai Inc., the U.S. pharmaceutical operation of Tokyo-based Eisai Co., Ltd., announced today that it has entered into an agreement with Arena Pharmaceuticals GmbH, a wholly owned subsidiary of Arena Pharmaceuticals, Inc., for exclusive U.S. rights to commercialize lorcaserin, a drug candidate for potential use in the treatment of obesity, including weight loss, for patients who are obese (Body Mass Index or BMI ≥ 30) or overweight (BMI ≥ 27) with at least one weight-related co-morbid condition.

1 Jul 2010

Evotec commences EVT 101 proof-of-concept Phase II study in treatment-resistant depression

Evotec AG today announced the start of the proof-of-concept Phase II study in treatment-resistant depression with its NR2B subtype selective NMDA receptor antagonist EVT 101. This clinical development is part of an alliance between Evotec and Roche.

1 Jul 2010

Research findings open new ways to enhance memory function and treat catastrophic brain diseases

For the first time, scientists have linked a brain compound called kynurenic acid to cognition, possibly opening doors for new ways to enhance memory function and treat catastrophic brain diseases, according to a new study from the University of Maryland School of Medicine. When researchers decreased the levels of kynurenic acid in the brains of mice, their cognition was shown to improve markedly, according to the study, which was published in the July issue of the journal Neuropsychopharmacology.

1 Jul 2010

Eisai reports preliminary results from Dacogen for Injection Phase III study in AML

Eisai Inc. announced today preliminary results from a randomized Phase III clinical trial of Dacogen® (decitabine) for Injection versus either a low-dose chemotherapy agent or supportive care in elderly patients with acute myeloid leukemia (AML), a life-threatening cancer of the blood that generally occurs in older adults.

1 Jul 2010

Neuroscience News and Research

New study may lead to in-car warning system that may provide enough time for drivers to react

Rejection by romantic partner associated with brain's motivation, reward and addiction craving centers

Scientists demonstrate how neural stem cells, precursor cells control growth of glioblastomas

ERA-Net NEURON names winners of 2009 Excellent Paper in Neuroscience award for young scientists

Depression increases risk of developing dementia later in life

The heart and the psyche – Link between heart disease and anxiety-depressive disorders

Karolinska Institutet researchers contribute at ESOF 2010

Wellcome-Wolfson Capital Awards initiative invests over 30M in large-scale university infrastructure projects

Study: ONGLYZA and metformin improve HbA1c levels for adult patients with type 2 diabetes at 76-weeks

Research may provide key to understanding interplay between exercise, aging and neurogenesis

AstraZeneca announces new support program for patients on ARIMIDEX

Euthymics and DOV sign merger agreement

University College London neurology professor becomes first recipient of Lord Brain Memorial Medal

Brain is intrinsically unreliable, says new research

New research identifies memory and brain scan as best tests for predicting Alzheimer's disease

Eisai to commercialize lorcaserin for obesity and weight management in U.S.

Eisai signs agreement with Arena Pharmaceuticals GmbH to commercialize lorcaserin

Evotec commences EVT 101 proof-of-concept Phase II study in treatment-resistant depression

Research findings open new ways to enhance memory function and treat catastrophic brain diseases

Eisai reports preliminary results from Dacogen for Injection Phase III study in AML

Neuroscience - Second Edition eBook

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News